Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.

Crosignani S, Jorand-Lebrun C, Campbell G, Prêtre A, Grippi-Vallotton T, Quattropani A, Bouscary-Desforges G, Bombrun A, Missotten M, Humbert Y, Frémaux C, Pâquet M, El Harkani K, Bradshaw CG, Cleva C, Abla N, Daff H, Schott O, Pittet PA, Arrighi JF, Gaudet M, Johnson Z.

ACS Med Chem Lett. 2011 Oct 10;2(12):938-42. doi: 10.1021/ml200223s. eCollection 2011 Dec 8.

2.

Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.

Crosignani S, Prêtre A, Jorand-Lebrun C, Fraboulet G, Seenisamy J, Augustine JK, Missotten M, Humbert Y, Cleva C, Abla N, Daff H, Schott O, Schneider M, Burgat-Charvillon F, Rivron D, Hamernig I, Arrighi JF, Gaudet M, Zimmerli SC, Juillard P, Johnson Z.

J Med Chem. 2011 Oct 27;54(20):7299-317. doi: 10.1021/jm200866y. Epub 2011 Oct 3.

PMID:
21916510
3.

Optimization of the Central Core of Indolinone-Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists.

Crosignani S, Jorand-Lebrun C, Page P, Campbell G, Colovray V, Missotten M, Humbert Y, Cleva C, Arrighi JF, Gaudet M, Johnson Z, Ferro P, Chollet A.

ACS Med Chem Lett. 2011 Jun 9;2(8):644-9. doi: 10.1021/ml2001196. eCollection 2011 Aug 11.

4.

Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway.

Guo X, Harada C, Namekata K, Matsuzawa A, Camps M, Ji H, Swinnen D, Jorand-Lebrun C, Muzerelle M, Vitte PA, Rückle T, Kimura A, Kohyama K, Matsumoto Y, Ichijo H, Harada T.

EMBO Mol Med. 2010 Dec;2(12):504-15. doi: 10.1002/emmm.201000103.

5.

GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.

Gobert RP, van den Eijnden M, Szyndralewiez C, Jorand-Lebrun C, Swinnen D, Chen L, Gillieron C, Pixley F, Juillard P, Gerber P, Johnson-Léger C, Halazy S, Camps M, Bombrun A, Shipp M, Vitte PA, Ardissone V, Ferrandi C, Perrin D, Rommel C, Hooft van Huijsduijnen R.

J Biol Chem. 2009 Apr 24;284(17):11385-95. doi: 10.1074/jbc.M807241200. Epub 2009 Feb 20.

6.

Convergent functional genomics of oligodendrocyte differentiation identifies multiple autoinhibitory signaling circuits.

Gobert RP, Joubert L, Curchod ML, Salvat C, Foucault I, Jorand-Lebrun C, Lamarine M, Peixoto H, Vignaud C, Frémaux C, Jomotte T, Françon B, Alliod C, Bernasconi L, Abderrahim H, Perrin D, Bombrun A, Zanoguera F, Rommel C, Hooft van Huijsduijnen R.

Mol Cell Biol. 2009 Mar;29(6):1538-53. doi: 10.1128/MCB.01375-08. Epub 2009 Jan 12.

7.

Identification, synthesis, and biological evaluation of novel pyrazoles as low molecular weight luteinizing hormone receptor agonists.

Jorand-Lebrun C, Brondyk B, Lin J, Magar S, Murray R, Reddy A, Shroff H, Wands G, Weiser W, Xu Q, McKenna S, Brugger N.

Bioorg Med Chem Lett. 2007 Apr 1;17(7):2080-5. Epub 2006 Dec 22.

PMID:
17321742
8.

Dimers of 5HT1 ligands preferentially bind to 5HT1B/1D receptor subtypes.

Perez M, Jorand-Lebrun C, Pauwels PJ, Pallard I, Halazy S.

Bioorg Med Chem Lett. 1998 Jun 2;8(11):1407-12.

PMID:
9871775
9.

5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.

Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S.

J Med Chem. 1997 Nov 21;40(24):3974-8.

PMID:
9397179

Supplemental Content

Loading ...
Support Center